相关临床试验
5
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
100.0%
暂无批准数据
- Elicera Therapeutics AB, a clinical-stage cell and gene therapy company, has appointed Johan Liwing as its new CEO effective September 1, 2026. - Liwing brings over 20 years of pharmaceutical and biotech experience spanning oncology, cell therapy, business development, and capital raising. - He previously served as CEO of Lipigon Pharmaceuticals and XNK Therapeutics, where he advanced programs to Phase 2 and established a GMP-certified cell therapy manufacturing facility. - Outgoing CEO Jamal El-Mosleh will remain with the company until October 31 to ensure an orderly leadership transition.
- The FDA granted Breakthrough Therapy Designation to MeiraGTx's AAV2-hAQP1 gene therapy for treating Grade 2 and Grade 3 radiation-induced xerostomia in cancer patients. - The designation was supported by 3-year data from a Phase 1 dose escalation study, with the Phase 2 AQUAx2 trial currently enrolling final patients. - MeiraGTx anticipates potential BLA filing in the first half of 2027 and US market launch targeted for early 2028. - The company secured significant strategic partnerships with Eli Lilly ($75 million upfront) and Hologen AI ($200 million upfront) to advance its gene therapy pipeline.
- Trial Library raised $10 million in Series A funding co-led by SemperVirens Venture Capital and Next Ventures to expand its AI-enabled platform that connects community healthcare providers with clinical trials. - The platform currently operates across 320+ clinics and 1,500+ providers nationwide, addressing the gap where 85% of cancer patients receive treatment in community settings but trials are concentrated in academic centers. - The company has demonstrated significant impact with 642 patient referrals in one year through The Oncology Institute partnership and focuses on diversity with 69% of referrals being non-white patients. - Strategic partnerships with major biopharmaceutical companies including Johnson & Johnson Innovative Medicine and collaborations with payers position Trial Library to make clinical trials a standard care option.
- The dry age-related macular degeneration market is expected to experience substantial growth through 2034, driven by the uptake of recently approved therapies and the anticipated launch of emerging treatments. - Multiple innovative therapies are advancing through clinical trials, including Gildeuretinol from Alkeus Pharmaceuticals, which demonstrated a 0.25 sq mm per year reduction in geographic atrophy lesion growth compared to placebo in its Phase II/III SAGA trial. - The United States represents the largest market opportunity with approximately 21 million prevalent cases in 2024, while dry AMD accounts for nearly 90% of all AMD cases, representing a vast untapped therapeutic opportunity.
- Pricing negotiations between the pan-Canadian Pharmaceutical Alliance and Johnson & Johnson for Carvykti, a CAR-T therapy for multiple myeloma, collapsed in September after nearly two years of discussions. - The therapy, approved by Health Canada in February 2023, has a sticker price of $632,455 and showed remarkable results with 33% of heavily pretreated patients remaining alive and progression-free at five years. - Nearly 1,000 Canadian multiple myeloma patients and caregivers have launched a letter-writing campaign urging officials to resume negotiations for the potentially curative treatment. - Multiple myeloma affects 11 Canadians daily, making it the second most common blood cancer, while Carvykti is already publicly reimbursed in 13 countries including Spain, Belgium, and Portugal.
- MeiraGTx received FDA RMAT designation for AAV-GAD in Parkinson's disease and aligned with the FDA on its Phase 2 AQUAx2 study for radiation-induced xerostomia to support potential BLA filing. - The company demonstrated significant disease-modifying effects in Parkinson's disease through FDG-PET imaging data showing changes in pathological basal ganglia circuitry, including the substantia nigra. - MeiraGTx is preparing to file for regulatory approval of AAV-AIPL1 for LCA4 in Q4 2025, with all 11 treated children showing meaningful responses and those blind at birth now able to see. - The company secured $200 million in funding through its strategic collaboration with Hologen AI to advance AAV-GAD development and other CNS therapies.
- The ten-year partnership between Johnson & Johnson Innovative Medicine and Karolinska Institutet has yielded significant scientific advances across nine disease areas, with researchers working side by side since 2015. - Over 150 researchers have participated in the collaboration, producing more than 30 scientific papers and 50 presentations at international conferences, focusing on critical medical needs in oncology, neurology, immunology, and ophthalmology. - The partnership exemplifies successful innovation through academic-industry collaboration, with both organizations now exploring new opportunities to develop innovative therapies for complex conditions like Alzheimer's disease and cancer.
- Six pharmaceutical facilities received category awards for innovation, operations, and social impact at the 2025 ISPE Europe Annual Conference, marking the 20th anniversary of the prestigious FOYA program. - Touchlight's synthetic DNA manufacturing facility and Johnson & Johnson's flexible packaging operations were among the winners recognized for advancing pharmaceutical manufacturing standards and sustainability initiatives. - The overall 2025 FOYA winner will be announced at a special black-tie celebration during the ISPE Annual Meeting & Expo in Charlotte, North Carolina in October 2025.
• MeiraGTx has secured a strategic collaboration with Hologen AI that includes a $200 million upfront payment and the formation of a joint venture with an additional $230 million in committed capital to advance AAV-GAD gene therapy for Parkinson's disease. • The partnership creates the first neuro-AI clinical drug development company, combining MeiraGTx's gene therapy expertise with Hologen's AI technology to transform CNS drug development for neurodegenerative and neuropsychiatric disorders. • Recent clinical data showed AAV-GAD therapy demonstrated significant benefits in Parkinson's disease patients, with meaningful improvements in motor function (UPDRS Part 3) and quality of life measures (PDQ-39).
- Johnson & Johnson Innovative Medicine is developing JNJ-2056, a novel liposomal vaccine targeting phospho-Tau (pTau) for the treatment of Alzheimer's disease and other tauopathies. - The vaccine candidate, based on SupraAntigen technology platform, represents a new approach in targeting tau protein accumulation, a hallmark of neurodegenerative diseases. - JNJ-2056 is designed for intramuscular administration, potentially offering a more convenient treatment option for patients with tauopathies.
